READ : Bloomberg 11/9/13The National Highway Traffic Safety Administration said Oct. 24 it found no evidence the first fire resulted from defects or violations of U.S. safety standards
( If they found no defect in 1st fire, 2nd fire was caused by metal piece also 3rd by driver going 120 per hr.)
Thanks for posting super.
Analysts: Facebook a Buy
Katey Troutman | More Articles
October 14, 2013
Page 1 of 4
Facebook (NASDAQ:FB): BMO Capital expects analysts to raise their estimates for Facebook’s stock as investors further digest the company’s opportunities in social TV and second-screen behavior. The firm recommends buying the stock ahead of the company’s results and keeps an Outperform rating on the shares
The Fly on The Wall 11/17/13
Stock Market & Financial Investment News
December 17, 2013
TSLA Tesla starting to take pre-orders in China, CNBC reports
Tesla is starting to take pre-orders in China for the Model S and Model X, CNBC reports. CEO Elon Musksaid earlier this year that the company could eventually sell 10,000 Model S vehicles a year in Europe and 5,000 in Asia
accelerated approvals on CDX-011 and Rindo. Also Phase III trials etc..
I see $60 easy.
Deutsche Bank Saying TSLA Will Be $200 ///////// LINK
Seeking Alpha Market Currents 10/4/13
Analysis: Tesla at $200 is coming
Deutsche Bank doesn't think a single car fire wrecks the bull thesis on Tesla Motors (TSLA)
Market Watch 11/21/13
Tesla Model S scores 99 out of 100 on Consumer Reports satisfaction survey
November 21, 2013, 10:55 AM
Why Tesla is the Top Auto Stock to Own
BY Chris Ciaccia | 12/03/13 -
Do The DD Folks:
Survey Finds 51% of Brands Prefer Advertising on Facebook image
Quite simply, brands prefer Facebook because it is by far the most populated social network. As of March of this year Facebook has claimed 1.1 billion active users worldwide. Among the largest markets, according to Socialbakers’ statistics, over 78% of Internet users in the United States are on Facebook, with 68% in the United Kingdom, and almost 76% in Australia. A social network of this magnitude produces connections between brands and fans, and friends of fans that were previously impossible to notice.
According to a recent survey conducted by Socialbakers, of the four of the biggest social networks Facebooktrumps Twitter, LinkedIn and YouTube. But there are reasons besides population size that make Facebook an exciting place for advertisers
10/10/13 12:35 P.M.
Mobile ads on the rise: US advertisers spent $3b in first half of 2013, up 60% on last year
As consumers are increasingly connecting to the Internet via their smartphones, advertisers are piling on the money to roll out mobile ads. In the first half of 2013, US advertisers spent $3 billion on mobile advertising, up from $1.2 billion a year earlier, according to estimates from the Interactive Advertising Bureau, the Wall Street Journal reports.
The share of mobile ad expenditure out of total online ad spending in the US more than doubled to 15 percent during the first half of the year, the data showed. In all, US advertisers spent $20.1 billion on Internetads during the period. Comparatively, TV ad spending will likely stand at around $66.35 billion for the whole of this year, research company eMarketer predicts
Seeking Alpha Market Currents 12/13/13
Advertising works on Twitter; RBC boosts price target
"A substantial 40% of Twitter (TWTR) advertisers reported improving ROI over the last six months and 40% have also increased their Twitter spend," says RBC Capital, upping its price target on Buy-rated Twitter to $60 from $33.
59% of respondents plan to increase ad spend with Twitter over the next twelve months.
Seeking Alpha Market Currents
Celldex reports interim rindopepimut data
Celldex Therapeutics (CLDX) is out with interim data from ReACT (rindopepimut in recurrent glioblastoma).
The company says the results "demonstrate promising signs of clinical activity" in Avastin naïve and refractory patients.
Dr. David A. Reardon (the lead investigator) calls the observed immune response generated by the drug"very exciting," while CMO Thomas Davis says that if "these multiple signals for immunologic and anti-tumor activity persist in the final data, it may establish a new perspective on the potential for immunotherapy."
Stock Market & Financial Investment News
November 24, 2013
15:06 EDT CLDX Celldex reports data on ongoing exploratory Phase 2 ReACT study of rindopepimut
Celldex Therapeutics reported interim data from its ongoing, exploratory Phase 2 ReACT study of rindopepimut in recurrent glioblastoma. Rindopepimut is an immunotherapeutic vaccine that targets the tumor specific oncogene EGFRvIII(v3). Patients with EGFRvIII-positive glioblastoma typically have a worse prognosis than the overall glioblastoma population, including poor long term survival. The ReACT results demonstrate promising signs of clinical activity in advanced patient populations, including patients both naïve and refractory to bevacizumab, Avastin. An update on long-term survival for the three completed Phase 2 frontline studies in EGFRvIII-positive glioblastoma was also presented and results continue to exceed outcomes seen in contemporary controls."Patients who have grown right though Avastin are resistant to all of our available therapies," said David Reardon, M.D. "The potent immune response generated by rindopepimut and preliminary signs of anti-tumor activity in the Avastin refractory patients in the ReACT study are very exciting. The additional signal of an improved survival outcome in Avastin naïve patients further supports the potential activity of rindopepimut. I look forward to the final results of this study and hope they confirm what we have seen so far."
always follow the options.